Development of Site-Specific, High-DAR Dual-Payload ADCs
Time: 3:00 pm
day: Scientific Program Day Two PM
Details:
- Addressing the clinical challenge of acquired resistance to single-payload ADCs by delivering two different payloads simultaneously to tumors
- Utilizing an innovative cell-free platform to create novel antibody-drug conjugates
- Showcasing dual-payload ADC approaches with superior preclinical in vitro and in vivo efficacy
